<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Consensus diagnostic criteria for idiopathic multicentric Castleman disease (iMCD)</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">I. Major criteria (need both)</td> </tr> <tr> <td class="indent1"> <ol class="numbers_to_nine"> <li>Histopathologic lymph node features consistent with the iMCD spectrum. Features along the iMCD spectrum include (need grade 2-3 for either regressive GCs or plasmacytosis at minimum): </li> </ol> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Regressed/atrophic/atretic germinal centers, often with expanded mantle zones composed of concentric rings of lymphocytes in an "onion skinning" appearance </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>FDC prominence </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Vascularity, often with prominent endothelium in the interfollicular space and vessels penetrating into the GCs with a "lollipop" appearance </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Sheetlike, polytypic plasmacytosis in the interfollicular space </li> </ul> </td> </tr> <tr> <td class="indent2"> <ul class="decimal_heading"> <li>Hyperplastic GCs </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ol class="numbers_to_nine" start="2"> <li>Enlarged lymph nodes (≥1 cm in short-axis diameter) in ≥2 lymph node stations </li> </ol> </td> </tr> <tr> <td class="subtitle1_single">II. Minor criteria (need at least 2 of 11 criteria with at least 1 laboratory criterion)</td> </tr> <tr> <td class="indent1"><strong>Laboratory:</strong>*</td> </tr> <tr> <td class="indent1"> <ol> <li>Elevated CRP (&gt;10 mg/L) or ESR (&gt;15 mm/hour)<sup>¶</sup> </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="2"> <li>Anemia (hemoglobin &lt;12.5 g/dL for males, hemoglobin &lt;11.5 g/dL for females) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="3"> <li>Thrombocytopenia (platelet count &lt;150 k/microL) or thrombocytosis (platelet count &gt;400 k/microL) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="4"> <li>Hypoalbuminemia (albumin &lt;3.5 g/dL) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="5"> <li>Renal dysfunction (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>) or proteinuria (total protein 150 mg/24 hours or 10 mg/100 mL) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="6"> <li>Polyclonal hypergammaglobulinemia (total gamma-globulin or immunoglobulin G &gt;1700 mg/dL) </li> </ol> </td> </tr> <tr> <td class="indent1"><strong>Clinical:</strong></td> </tr> <tr> <td class="indent1"> <ol> <li>Constitutional symptoms: Night sweats, fever (&gt;38°C), weight loss, or fatigue (≥2 CTCAE lymphoma score for B-symptoms) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="2"> <li>Large spleen and/or liver </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="3"> <li>Fluid accumulation: Edema, anasarca, ascites, or pleural effusion </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="4"> <li>Eruptive cherry hemangiomatosis or violaceous papules </li> </ol> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ol start="5"> <li>Lymphocytic interstitial pneumonitis </li> </ol> </td> </tr> <tr> <td class="subtitle1_single">III. Exclusion criteria (must rule out each of these diseases that can mimic iMCD)</td> </tr> <tr> <td class="indent1"><strong>Infection-related disorders:</strong></td> </tr> <tr> <td class="indent1"> <ol> <li>HHV-8 (infection can be documented by blood PCR, diagnosis of HHV-8–associated MCD requires positive LANA-1 staining by IHC, which excludes iMCD) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="2"> <li>Clinical EBV-lymphoproliferative disorders such as infectious mononucleosis or chronic active EBV (detectable EBV viral load not necessarily exclusionary) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="3"> <li>Inflammation and adenopathy caused by other uncontrolled infections (eg, acute or uncontrolled CMV, toxoplasmosis, HIV, active tuberculosis) </li> </ol> </td> </tr> <tr> <td class="indent1"><strong>Autoimmune/autoinflammatory diseases (requires full clinical criteria, detection of autoimmune antibodies alone is not exclusionary):</strong></td> </tr> <tr> <td class="indent1"> <ol> <li>Systemic lupus erythematosus </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="2"> <li>Rheumatoid arthritis </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="3"> <li>Adult-onset Still disease </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="4"> <li>Juvenile idiopathic arthritis </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="5"> <li>Autoimmune lymphoproliferative syndrome </li> </ol> </td> </tr> <tr> <td class="indent1"><strong>Malignant/lymphoproliferative disorders (these disorders must be diagnosed before or at the same time as iMCD to be exclusionary):</strong></td> </tr> <tr> <td class="indent1"> <ol> <li>Lymphoma (Hodgkin and non-Hodgkin) </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="2"> <li>Multiple myeloma </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="3"> <li>Primary lymph node plasmacytoma </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="4"> <li>FDC sarcoma </li> </ol> </td> </tr> <tr> <td class="indent1"> <ol start="5"> <li>POEMS syndrome<sup>Δ</sup> </li> </ol> </td> </tr> <tr> <td class="indent1"><strong>Select additional features supportive of, but not required for diagnosis:</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Elevated IL-6, sIL-2R, VEGF, IgA, IgE, LDH, and/or B2M </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Reticulin fibrosis of bone marrow (particularly in patients with TAFRO syndrome) </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Diagnosis of disorders that have been associated with iMCD: Paraneoplastic pemphigus, bronchiolitis obliterans organizing pneumonia, autoimmune cytopenias, polyneuropathy (without diagnosing POEMS<sup>Δ</sup>), glomerular nephropathy, inflammatory myofibroblastic tumor </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">GC: germinal center; FDC: follicular dendritic cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; eGFR: estimated glomerular filtration rate; CTCAE: common terminology for adverse events; PCR: polymerase chain reaction; LANA-1: latency-associated nuclear antigen; IHC: immunohistochemistry; EBV: Epstein-Barr virus; CMV: cytomegalovirus; IL: interleukin; VEGF: vascular endothelial growth factor; Ig: immunoglobulin; LDH: lactate dehydrogenase; B2M: β-2-microglobulin. <br/>* We have provided laboratory cutoff thresholds as guidance, but we recognize that some laboratories have slightly different ranges. We suggest that you use the upper and lower ranges from your particular laboratory to determine if a patient meets a particular laboratory Minor criterion.<br/>¶ Evaluation of CRP is mandatory and tracking CRP levels is highly recommended, but ESR will be accepted if CRP is not available.<br/>Δ POEMS is considered to be a disease "associated" with Castleman's disease. Because the monoclonal plasma cells are believed to drive the cytokine storm, we do not consider it iMCD, but rather "POEMS-associated MCD."</div><div class="graphic_reference">Reproduced with permission of the American Society of Hematology, from: Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood 2017; 129:1646; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2017.</div><div id="graphicVersion">Graphic 112477 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
